Proteins of resistance and drug resistance in ovarian carcinoma patients;Proteiny rezistence a chemorezistence u pacientek s karcinomem ovaria

Klinicka Onkologie

Volumn 25, Issue 6, 2012, Pages 457-463

  Sedláková, Iva ^a   Laco, J ^b   Tosner J ^a   Caltova K ^c   Cervinka M ^c   Rezac A ^a   Spacek J ^a   Skapinec P ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b Fingerland v Ústav Patologie Fakultní Nemocnice Hradec Králové   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Drug resistance; LRP lung resistance protein; MRP1 protein; MTT test; Ovarian cancer; P170 glycoprotein

Indexed keywords

LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 5; ANTINEOPLASTIC AGENT; RIBONUCLEOPROTEIN;

ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; EARLY CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; METABOLISM; MULTIDRUG RESISTANCE; NEOPLASM; OVARIAN EPITHELIAL CANCER; OVARY TUMOR;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; VAULT RIBONUCLEOPROTEIN PARTICLES;

MLCS; MLOWN;

EID: 84872474450     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Cibula D, Petruželka L et al. Onkogynekologie. Praha: Grada Publishing 2009.
2. Fruehauf PJ, Alberts DS. In vitro drug resistance versus chemosensitivity: two sides of different coins. J Clin Oncol 2005; 23(15): 3641-3643.
3. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds). Cancer: principles and practice of oncology. 6th ed. Philadelphia: Lippincott-Raven 2001: 597-632.
4. Nosková V, Hajdúch M, Mihál V et al. Mechanismy mnohočetné lékové rezistence a jejich význam pro klinickou praxi I. typická MDR. Klin Onkol 2000; 13(2): 4-9.
5. Václavíková R, Hubáčková M, Kubala E et al. Exprese genu mnohočetné lékové rezistence 1 (MDR1) a její význam v rozvoji a terapii karcinomu prsu. Klin Onkol 2007; 20(3): 253-259.
6. Zhang JT. The multi-structural feature of the multidrug resistance gene product P-glycoprotein: implications for its mechanism of action (hypothesis). Mol Membr Biol 2001; 18(2): 145-152.
7. Kuwano M, Uchiumi T, Hayakawa H et al. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci 2003; 94(1): 9-14. (Pubitemid 36575851)
8. Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barier. Adv Drug Deliv Rev 1999; 36(2-3): 179-194.
9. Larkin A, O'Driscoll L, Kennedy S et al. Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study Int J Cancer 2004; 112(2): 286-294. (Pubitemid 39244369)
10. Schneider J, Gonzales-Roces S, Pollán M et al. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy. Breast Cancer Res 2001; 3(3): 183-191. (Pubitemid 32390219)
11. Seymour L, Bezwoda WR, Dansey RD. P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer. Breast Cancer Res Treat 1995; 36(1): 61-69.
12. Izquirerdo MA, van der Zee AG, Vermorken JB et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995; 87(16): 1230-1237.
13. Goff BA, Paley PJ, Greer BE et al. Evaluation of chemo-resistance markers in woman with epithelial ovarian carcinoma. Gynecol Oncol 2001; 81(1): 18-24. (Pubitemid 32368072)
14. Arts HJ, Katsaros D, de Vries EG et al. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated proetin 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res 1999; 5(10): 2798-2805. (Pubitemid 29493954)
15. Materna V, Pleger J, Hoffman U et al. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 2004; 94(1): 152-160. (Pubitemid 38950512)
16. Sedláková I, Tošner J, Řezáč A et al. Rezistence/sensitivita in vitro u pacientek s karcinomem ovaria. Česk Gynekol 2011; 76(3): 184-189.
17. Xing H, Wang S, Weng D et al. Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids. Oncol Rep 200; 17(1): 117-122.
18. Kamazawa S, Kigawa J, Kanamori Y et al. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol 2002; 86(2): 171-176. (Pubitemid 34953500)
19. Scheffer GL, Kool M, Heijn M et al. Specific detection of multidrug resistance proteins MRP, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res 2000; 60(18): 5269-5277.
20. Odening KE, Rutz R, Laufs S et al. Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells. Clin Exp Immunol 2008; 155(2): 239-248.
21. Kavallaris M, Leary JA, Barrett JA et al. MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors. Cancer Lett 1996; 102(1-2): 7-16. (Pubitemid 26097798)
22. Baekelandt MM, Holm R, Nesland JM et al. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res 2000; 20(2B): 1061-1067. (Pubitemid 30240677)
23. Raspollini MR, Amunni G, Villanucci A et al. Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer 2004; 14(5): 815-823. (Pubitemid 39238165)